Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Compugen Ltd CGEN

Healthcare Biotechnology
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company... see more

Recent & Breaking News (NDAQ:CGEN)

A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy

PR Newswire October 9, 2017

Mid-Morning Market Update: Markets Open Lower; Lowe's Earnings Miss Expectations

Benzinga.com  August 23, 2017

Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month

PR Newswire August 7, 2017

Compugen Welcomes Paul Sekhri as its New Chairman of the Board

PR Newswire August 2, 2017

Compugen Reports Second Quarter 2017 Results

PR Newswire August 2, 2017

20 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  July 26, 2017

Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology

PR Newswire July 26, 2017

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  July 25, 2017

Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate

PR Newswire July 25, 2017

Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET

PR Newswire July 24, 2017

Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models

PR Newswire June 5, 2017

Compugen Provides Update on COM701 and Upcoming Presentations

PR Newswire May 31, 2017

Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors

PR Newswire May 25, 2017

Compugen to Present at Two Upcoming Investor Conferences in June

PR Newswire May 23, 2017

Investor Network: Compugen Ltd. to Host Earnings Call

Accesswire May 9, 2017

Compugen Reports First Quarter 2017 Results

PR Newswire May 9, 2017

Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO

PR Newswire May 4, 2017

Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET

PR Newswire April 26, 2017

Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program

PR Newswire March 28, 2017

Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences

PR Newswire March 22, 2017